Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

181. Indacaterol maleate, glycopyrronium bromide (Ultibro Breezhaler) - maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Indacaterol maleate, glycopyrronium bromide (Ultibro Breezhaler) - maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Published 08 December 2014 Product Update: indacaterol maleate 143micrograms (equivalent to 110microgram indacaterol) with glycopyrronium bromide 63micrograms (equivalent to 50microgram glycopyrronium) inhalation powder hard capsules (Ultibro ® Breezhaler ® 85microgram/43microgram [delivered dose (...) Scotland. Indication under review: maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). For patients in whom the combination of indacaterol maleate and glycopyrronium bromide is an appropriate choice of therapy, Ultibro ® Breezhaler ® provides the two ingredients in a single hard capsule at a lower cost than the individual components. Advice context: No part of this advice may be used without the whole of the advice being quoted

Scottish Medicines Consortium2014

182. Self-care support for people with COPD

Self-care support for people with COPD Self-care support for people with COPD Self-care support for people with COPD Centre for Reviews and Dissemination Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Centre for Reviews and Dissemination. Self-care support for people with COPD. University of York. Evidence briefings. 2014 Authors (...) ' conclusions As the prevalence of long-term conditions increases there is a greater focus on encouraging people to manage their condition(s). Self-care has been identified as integral to maintaining the health and wellbeing of people with COPD. There is consistent evidence that multicomponent interventions reduce respiratory-related hospital admissions and improve quality of life for people with COPD. Multicomponent interventions that include action plans, exercise, education and smoking cessation

Health Technology Assessment (HTA) Database.2014

183. Withdrawal of inhaled glucocorticoids and exacerbations of COPD.

Withdrawal of inhaled glucocorticoids and exacerbations of COPD. 25196117 2014 10 02 2014 10 14 2015 11 19 1533-4406 371 14 2014 Oct 02 The New England journal of medicine N. Engl. J. Med. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. 1285-94 10.1056/NEJMoa1407154 Treatment with inhaled glucocorticoids in combination with long-acting bronchodilators is recommended in patients with frequent exacerbations of severe chronic obstructive pulmonary disease (COPD). However, the (...) benefit of inhaled glucocorticoids in addition to two long-acting bronchodilators has not been fully explored. In this 12-month, double-blind, parallel-group study, 2485 patients with a history of exacerbation of COPD received triple therapy consisting of tiotropium (at a dose of 18 μg once daily), salmeterol (50 μg twice daily), and the inhaled glucocorticoid fluticasone propionate (500 μg twice daily) during a 6-week run-in period. Patients were then randomly assigned to continued triple therapy

NEJM2014

184. Withdrawal of inhaled glucocorticoids and exacerbations of COPD.

Withdrawal of inhaled glucocorticoids and exacerbations of COPD. BACKGROUND: Treatment with inhaled glucocorticoids in combination with long-acting bronchodilators is recommended in patients with frequent exacerbations of severe chronic obstructive pulmonary disease (COPD). However, the benefit of inhaled glucocorticoids in addition to two long-acting bronchodilators has not been fully explored. METHODS: In this 12-month, double-blind, parallel-group study, 2485 patients with a history (...) of exacerbation of COPD received triple therapy consisting of tiotropium (at a dose of 18 μg once daily), salmeterol (50 μg twice daily), and the inhaled glucocorticoid fluticasone propionate (500 μg twice daily) during a 6-week run-in period. Patients were then randomly assigned to continued triple therapy or withdrawal of fluticasone in three steps over a 12-week period. The primary end point was the time to the first moderate or severe COPD exacerbation. Spirometric findings, health status, and dyspnea

NEJM2014

185. Stepping Down Therapy in COPD.

Stepping Down Therapy in COPD. Stepping down therapy in COPD. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 25196116 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add (...) to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2014 Oct 2;371(14):1340-1. doi: 10.1056/NEJMe1409219. Epub 2014 Sep 8. Stepping down therapy in COPD. 1 . 1 From the Department of Medicine, University of Pittsburgh, Pittsburgh. Comment on [N Engl J Med. 2014] PMID: 25196116 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments How to cite

NEJM2014

186. Performance of the BODE index in patients with alpha1-antitrypsin deficiency-related COPD

Performance of the BODE index in patients with alpha1-antitrypsin deficiency-related COPD 24525449 2014 07 01 2015 02 24 2014 07 01 1399-3003 44 1 2014 Jul The European respiratory journal Eur. Respir. J. Performance of the BODE index in patients with α1-antitrypsin deficiency-related COPD. 78-86 10.1183/09031936.00168113 The BODE (body mass index, airflow obstruction, dyspnoea and exercise capacity) index is used to decide on referral and transplantation of patients (...) with chronic obstructive pulmonary disease (COPD). The BODE index has not been validated in patients with α1-antitrypsin deficiency, who account for 15% of COPD patients undergoing lung transplantation. We sought to validate the BODE index in α1-antitrypsin deficiency-related COPD. We assessed the prognostic value of the BODE index in 191 patients followed from 2006 to 2012 in a French prospective cohort of patients with α1-antitrypsin deficiency. 20 patients died during follow-up and 22 underwent lung transplantation. Survival (95% CI

EvidenceUpdates2014 Full Text: Link to full Text with Trip Pro

187. What are the benefits and risks of inhaled corticosteroids for COPD?

What are the benefits and risks of inhaled corticosteroids for COPD? What are the benefits and risks of inhaled corticosteroids for COPD? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics What are the benefits and risks of inhaled corticosteroids for COPD? View/ Open Date 2014-05 Format Metadata Abstract Q: What (...) are the benefits and risks of inhaled corticosteroids for COPD? A: Inhaled corticosteroids (ICS), either alone or with a long-acting [beta] agonist (LABA), reduce the frequency of exacerbations of chronic obstructive pulmonary disease (COPD) and statistically, but not clinically, improve quality of life (QOL) (strength of recommendation [SOR]: B, meta-analyses of heterogeneous studies). However, ICS have no mortality benefit and don’t consistently improve forced expiratory volume in 1 second (FEV1) (SOR: B

Clinical Inquiries2014

188. Ultibro Breezhaler (Indacaterol maleate, glycopyrronium bromide) - COPD

Ultibro Breezhaler (Indacaterol maleate, glycopyrronium bromide) - COPD HAS - Medical, Economic and Public Health Assessment Division 1/24 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 7 May 2014 ULTIBRO BREEZHALER 85 µg/43 µg, inhalation powder, hard capsule B/6 hard capsules + 1 inhaler (CIP: 34009 275 662 4 0) B/30 hard capsules + 1 inhale (CIP: 34009 275 664 7 9) Applicant: NOVARTIS INN Indacaterol maleate, glycopyrronium bromide ATC Code (2013 (...) ): R03AL04 (adrenergics in combination with anticholinergics) Reason for the request Inclusion Lists concerned B/30 hard capsules: National Health Insurance (French Social Security Code L.162-17) B/6 hard capsules: Hospital use (French Public Health Code L.5123 2) Indication concerned "ULTIBRO BREEZHALER is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease." HAS - Medical, Economic and Public Health Assessment Division 2

Haute Autorite de sante2014

189. Aclidinium in the management of COPD. Besides an anticholinergic agent, what else do we know about this drug?

Aclidinium in the management of COPD. Besides an anticholinergic agent, what else do we know about this drug? 2014. DAR No 1. Aclidinium, as maintenance therapy in the management of COPD (Bretaris Genuair®, Eklira Genuair®) - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : : : DAR No 1. Aclidinium, as maintenance therapy in the management of COPD (Bretaris Genuair®, Eklira Genuair®) DAR No 1. Aclidinium, as maintenance therapy (...) in the management of COPD (Bretaris Genuair®, Eklira Genuair®) Content tools Share it Besides an anticholinergic agent, what else do we know about this drug? There is no head-to-head trial comparing aclidinium vs other long-acting bronchodilators. Compared to placebo, aclidinium 400 mcg/12h improves spirometry parameters although the clinical relevance of this improvement is modest. Adverse effects related to heart conduction have been reported, and the EMA has requested a post-approval study to monitor

Drug and Therapeutics Bulletin of Navarre (Spain)2014

190. Should you consider antibiotics for exacerbations of mild COPD?

Should you consider antibiotics for exacerbations of mild COPD? Should you consider antibiotics for exacerbations of mild COPD? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Should you consider antibiotics for exacerbations of mild COPD? View/ Open Date 2014-04 Format Metadata Abstract Consider antibiotics (...) for patients with exacerbations of mild to moderate chronic obstructive pulmonary disease (COPD). URI Part of Citation Journal of Family Practice, 64(4): 2014: E11-E13 Collections hosted by hosted by

PURLS2014

191. Beclometasone dipropionate (Fostair) - Symptomatic treatment of patients with severe COPD

Beclometasone dipropionate (Fostair) - Symptomatic treatment of patients with severe COPD Published 07 July 2014 Product Update: beclometasone dipropionate and formoterol fumarate dihydrate metered dose inhaler 100microgram / 6microgram (Fostair ® ) (No: 976/14) Chiesi Ltd 06 June 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice (...) is summarised as follows: ADVICE: following an abbreviated submission beclometasone dipropionate and formoterol fumarate dihydrate metered dose inhaler 100microgram / 6microgram (Fostair ® ) is accepted for use within NHS Scotland. Indication under review: Symptomatic treatment of patients with severe COPD (FEV 1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. Fostair ® should be used in patients for whom

Scottish Medicines Consortium2014

192. Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index

Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index 24077342 2014 06 11 2014 06 24 2014 08 11 1931-3543 145 5 2014 May Chest Chest Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index. 972-80 No valid tools exist for evaluating the prognosis in the short and medium term after hospital discharge of patients with COPD. Our hypothesis was that a new index based on the CODEX (comorbidity, obstruction, dyspnea (...) , and previous severe exacerbations) index can accurately predict mortality, hospital readmission, and their combination for the period from 3 months to 1 year after discharge in patients hospitalized for COPD. A multicenter study of patients hospitalized for COPD exacerbations was used to develop the CODEX index, and a different patient cohort was used for validation. Comorbidity was measured using the age-adjusted Charlson index, whereas dyspnea, obstruction, and severe exacerbations were calculated

EvidenceUpdates2014

193. Fluticasone furoate/vilanterol (Relvar Ellipta) - symptomatic treatment of adults with chronic obstructive pulmonary disease (COPD)

Fluticasone furoate/vilanterol (Relvar Ellipta) - symptomatic treatment of adults with chronic obstructive pulmonary disease (COPD)

Scottish Medicines Consortium2014

194. Target lobe volume reduction and COPD outcome measures after endobronchial valve therapy

Target lobe volume reduction and COPD outcome measures after endobronchial valve therapy 23845721 2014 02 03 2014 10 16 2016 11 25 1399-3003 43 2 2014 Feb The European respiratory journal Eur. Respir. J. Target lobe volume reduction and COPD outcome measures after endobronchial valve therapy. 387-96 10.1183/09031936.00133012 Endobronchial valve (EBV) therapy may be associated with improvements in chronic obstructive pulmonary disease-related outcomes and may therefore be linked to improvements (...) in the body mass index, airflow obstruction, dyspnoea, exercise capacity (BODE) index. Data from 416 patients with advanced emphysema and hyperinflation across Europe and USA, who were randomised to EBV (n=284) or conservative therapy (n=132) were analysed. Quantitative image analysis was used to compare the volume of the targeted lobe at baseline and at 6 months to determine target lobe volume reduction (TLVR). 44% of patients receiving EBV therapy (versus 24.7% of controls) had clinically significant improvements

EvidenceUpdates2014 Full Text: Link to full Text with Trip Pro

195. The Impact of Coexisting COPD on Survival of Patients With Early-Stage Non-small Cell Lung Cancer Undergoing Surgical Resection

The Impact of Coexisting COPD on Survival of Patients With Early-Stage Non-small Cell Lung Cancer Undergoing Surgical Resection 24008835 2014 02 04 2014 04 21 2016 10 19 1931-3543 145 2 2014 Feb Chest Chest The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection. 346-53 10.1378/chest.13-1176 COPD is a recognized risk factor for lung cancer, but studies of coexisting COPD in relation to lung cancer outcomes are limited. We (...) assessed the impact of COPD on overall survival (OS) and progression-free survival (PFS) in patients with early-stage non-small cell lung cancer (NSCLC). Patients (N = 902) with early-stage (stage IA-IIB) NSCLC treated with surgical resection were retrospectively analyzed. The association of self-reported, physician-diagnosed COPD with survivals of NSCLC was assessed using the log-rank and Cox regression models, adjusting for age, sex, BMI, smoking, stages, and performance status. Among this cohort

EvidenceUpdates2014 Full Text: Link to full Text with Trip Pro

196. Adrenomedullin refines mortality prediction by the BODE index in COPD: the ``BODE-A`` index

Adrenomedullin refines mortality prediction by the BODE index in COPD: the ``BODE-A`` index 23794469 2014 02 03 2014 10 16 2015 11 19 1399-3003 43 2 2014 Feb The European respiratory journal Eur. Respir. J. Adrenomedullin refines mortality prediction by the BODE index in COPD: the "BODE-A" index. 397-408 10.1183/09031936.00058713 The BODE (body mass index, airflow obstruction, dyspnoea, exercise capacity) index is well-validated for mortality prediction in chronic obstructive pulmonary disease (...) (COPD). Concentrations of plasma pro-adrenomedullin, a surrogate for mature adrenomedullin, independently predicted 2-year mortality among inpatients with COPD exacerbation. We compared accuracy of initial pro-adrenomedullin level, BODE and BODE components, alone or combined, in predicting 1-year or 2-year all-cause mortality in a multicentre, multinational observational cohort with stable, moderate to very severe COPD. Pro-adrenomedullin was significantly associated (p<0.001) with 1-year mortality

EvidenceUpdates2014 Full Text: Link to full Text with Trip Pro

197. Smokers with COPD as Compared to Smokers Without COPD Have No Significant Difference in Oral Health

Smokers with COPD as Compared to Smokers Without COPD Have No Significant Difference in Oral Health UTCAT2690, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Smokers with COPD as Compared to Smokers Without COPD Have No Significant Difference in Oral Health Clinical Question In adult smokers with COPD, are the oral impairments significantly worse than in matched smokers without COPD? Clinical Bottom Line The oral (...) susceptibly for smokers with COPD does not significantly differ from smokers without COPD. Bergstrom concluded in a case controlled study that harmful effects of smoking do not affect an association between COPD and periodontitis. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Bergstrom/2013 Matched groups of smokers with COPD and without COPD Case Control Key results Both matched groups (in tobacco levels

UTHSCSA Dental School CAT Library2014

198. Roflumilast for stable COPD, another example of hasty positioning in (some) Clinical Practice Guidelines

Roflumilast for stable COPD, another example of hasty positioning in (some) Clinical Practice Guidelines Volumen 21. DTB: Vol 21, No 4. August - October 2013 - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : : : DTB: Vol 21, No 4. August - October 2013 DTB: Vol 21, No 4. August - October 2013 Content tools Share it Roflumilast for stable COPD, another example of hasty positioning in (some) Clinical Practice Guidelines In the management (...) of stable COPD, roflumilast has only shown an improvement in lung function and a modest reduction in exacerbations when compared to placebo. However, there are no data on roflumilast efficacy incorporated into therapeutic regimens commonly employed in clinical practice. There is concern regarding the safety profile of the drug and it is under an extensive risk management plan. The positioning of roflumilast is different in the three aforementioned guidelines: 1) as an alternative to inhaled

Drug and Therapeutics Bulletin of Navarre (Spain)2014

199. Complex interventions that reduce urgent care use in COPD: a systematic review with meta-regression

Complex interventions that reduce urgent care use in COPD: a systematic review with meta-regression Complex interventions that reduce urgent care use in COPD: a systematic review with meta-regression Complex interventions that reduce urgent care use in COPD: a systematic review with meta-regression Dickens C, Katon W, Blakemore A, Khara A, Tomenson B, Woodcock A, Fryer A, Guthrie E CRD summary This well-conducted review concluded that complex interventions (...) for chronic obstructive pulmonary disease (COPD) may reduce the use of urgent care. The conclusion reflects the evidence and is appropriately cautious given the variety of interventions included in the review. Authors' objectives To identify the effects of complex interventions in reducing the use of urgent healthcare among people with chronic obstructive pulmonary disorder (COPD). Searching MEDLINE, EMBASE, PsycINFO, CINAHL, BNI and The Cochrane Library were searched from inception to January 2013; search strategies were reported

DARE.2014

200. Umeclidinium in patients with COPD: a randomised, placebo-controlled study

Umeclidinium in patients with COPD: a randomised, placebo-controlled study 23949963 2014 01 01 2014 09 01 2014 09 16 1399-3003 43 1 2014 Jan The European respiratory journal Eur. Respir. J. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. 72-81 10.1183/09031936.00033213 Efficacy and safety of umeclidinium administered in a dry power inhaler were evaluated in moderate-to-very-severe chronic obstructive pulmonary disease patients. This was a randomised, placebo (...) Respiratory Questionnaire total score for both UMEC doses (-7.9 and -10.87 units, for UMEC 62.5 mg and 125 mg, respectively; both p,0.001) were noted compared with placebo at week 12 [DOSAGE ERROR CORRECTED].The incidence of adverse events was low and similar across treatments. Umeclidinium 62.5 and 125 μg significantly improved lung function, dyspnoea and health status compared with placebo, and were well tolerated in chronic obstructive pulmonary disease patients over 12 weeks. Trivedi Roopa R

EvidenceUpdates2014